Search academic texts

Information × Registration Number 0212U007160, 0111U000518 , R & D reports Title Fundamentals of technology a new putative antitumour cytokine EMAP II and its mutant forms with increased antiangiogenic effect popup.stage_title Head Kornelyuk Alexander Ivanovich, Registration Date 27-06-2012 Organization Institute of Molecular Biology and Genetics popup.description2 Creating a scientific basis for genetically engineered biotechnology receiving anti-tumor cytokine EMAP II (endothelial monocyte-activating and polypeptides II) as a mediator of anti-angiogenic action and its mutant forms with increased activity. In the course of the project were developed optimized conditions for bacterial expression of human cytokine EMAP II in preparative quantities as a new biotechnological product. Means of computer simulation was created a molecular model of the interaction of cytokine EMAP II receptor integrins 5 3, and suggested approaches to enhance its anti-angiogenic action directed by changes in amino acid residues in the center of the binding to the receptor. At the time the project was to investigate the influence of drugs received EMAP II on growth and morphology of malignant tumors on the model of transplanted human prostate adenocarcinoma fragments in mice. These results will form the basis for the creation of domestic production technology of genetic engineering of new drugs based on the antitumor effect of cytokine EMAP II. Product Description popup.authors Козлов Олександр Вадимович Кордиш Марія Олександрівна Ложко Дмитро Миколайович Резніков Олександр Григорович Чайковська Людмила В'ячеславівна popup.nrat_date 2020-04-02 Close